Key clinical point: Rimegepant was effective for the acute treatment of migraine in patients who responded inadequately to 1 or ≥2 triptans and in current triptan users.
Major finding: Rimegepant was more effective than placebo at 2 hours postdose in providing freedom from pain and the most bothersome symptom (MBS) in patients with an inadequate response to 1 (both P < .001) and ≥2 (P = .013 and P < .001, respectively) triptans and in current triptan users (both P < .001). Among triptan-naive patients, rimegepant vs placebo significantly improved pain freedom (P = .007) but not MBS (P = .06).
Study details: This was a post hoc analysis of three phase 3 randomized controlled trials including 3507 patients with migraine who had (35.2%) or did not have (64.8%) inadequate response to triptans and who received rimegepant (n = 1749) or placebo (n = 1758).
Disclosures: This study was funded by Biohaven Pharmaceuticals, Inc. Six authors declared being employees of or holding stocks in Biohaven. Some authors declared ties with various sources.
Source: Lipton RB et al. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. Cephalalgia. 2023;43(2):3331024221141686 (Feb 5). Doi: 10.1177/03331024221141686